Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to a durable effect for a drug that ...
Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...
PHOENIX — Answering pleas of parents of disabled adult children, a Senate panel resurrected legislation Wednesday to require that new or extensively remodeled bathrooms in public buildings have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback